CIBC Asset Management Inc Has $2.29 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

CIBC Asset Management Inc decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 68.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,166 shares of the life sciences company’s stock after selling 38,019 shares during the period. CIBC Asset Management Inc’s holdings in Illumina were worth $2,294,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Versant Capital Management Inc lifted its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new position in Illumina during the fourth quarter worth $32,000. TD Private Client Wealth LLC lifted its holdings in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares during the period. V Square Quantitative Management LLC boosted its stake in shares of Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 132 shares in the last quarter. Finally, Private Trust Co. NA grew its holdings in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Down 3.1 %

Illumina stock opened at $94.20 on Friday. The company’s 50 day simple moving average is $127.98 and its 200 day simple moving average is $134.01. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a market capitalization of $14.92 billion, a price-to-earnings ratio of -12.27, a PEG ratio of 1.70 and a beta of 1.10. Illumina, Inc. has a fifty-two week low of $93.50 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ILMN shares. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada cut their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group decreased their price target on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, February 7th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and cut their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Guggenheim reduced their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Illumina presently has an average rating of “Moderate Buy” and an average target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.